The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%.

The Business Research Company The Business Research Company's Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Global Market Report. Tuesday, 02 January 2024 12:17 GMT.

However, the current understanding of glucagon-like peptide-1 actions in renal pathways is inadequate. In rodent and human kidneys, GLP-1 receptors are present in vascular smooth muscles rather ...

The incretin hormone glucagon-like peptide 1 (GLP-1), as well as GLP-1 analogues that are now being used for the treatment of patients with type 2 diabetes, potently suppresses α-cell secretion.

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

About The Article: This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA ...

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results.&ldquo ...

By Vijay Kumar Malesu Subgroup analyses reveal GLP-1 RAs may reduce alcohol cravings and brain cue reactivity. Study: Association between glucagon-like peptide-1 receptor agonists use and change ...

DALLAS — Results presented at the American Association of Hip and Knee Surgeons Annual Meeting showed 14 days may be the optimal cutoff time for glucagon-like peptide-1 receptor agonists prior ...

Study: Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.Image Credit: Kmpzzz/Shutterstock.com. In a recent study published ...